Cerebrovascular Disease News and Research

RSS

Cerebrovascular disease is a group of brain dysfunctions related to disease of the blood vessels supplying the brain. Hypertension is the most important cause; it damages the blood vessel lining, endothelium, exposing the underlying collagen where platelets aggregate to initiate a repairing process which is not always complete and perfect. Sustained hypertension permanently changes the architecture of the blood vessels making them narrow, stiff, deformed, uneven and more vulnerable to fluctuations in blood pressure.

Study finds link between fasting serum glucose levels and in-hospital mortality in elderly non-diabetic patients

A two-country hospital study of 808 elderly patients found a strong association between high, undiagnosed blood glucose in non-diabetic patients and increased hospital death rates, according to the March issue of IJCP, the International Journal of Clinical Practice.

24 Feb 2011

Novartis FLUAD seasonal flu vaccine for older adults receives Health Canada approval

Health Canada has approved FLUAD, a Novartis seasonal flu vaccine for adults 65 years and older. Canadian seniors are the hardest hit of all age groups by seasonal influenza and account for 90 per cent of influenza deaths and 70 per cent of hospitalizations.

22 Feb 2011

SBUMC to unveil one-of-a-kind neuroendovascular simulator

Stony Brook University Medical Center will unveil this Friday a one-of-a-kind neuroendovascular simulator that recreates vasculature in the brain, including scenarios of damaged vessels from acute stroke, brain aneurysms, and other cerebrovascular anomalies. Affectionately known in the lab as "Headley".

16 Dec 2010

China Nuokang receives SFDA manufacturing license for Dipyridamole Aspirin

China Nuokang Bio-Pharmaceutical Inc., a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company has received the manufacturing license from the State Food and Drug Administration ("SFDA") for Dipyridamole Aspirin, a stroke-prevention product developed in-house.

15 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Underwood-Memorial Hospital joins Jefferson Neuroscience Network as New Jersey participant

Underwood-Memorial Hospital of Woodbury, New Jersey has joined the Jefferson Neuroscience Network (JNN) as one of the first New Jersey participants. Through this collaboration, Jefferson and Underwood will provide some of the most sophisticated care and expertise available to patients with time-sensitive neurovascular diseases.

1 Dec 2010

Gender-related disparity in outcomes of lower extremities peripheral arterial disease continues: Study

Researchers from the Mount Sinai School of Medicine report that despite overall improvement, there is still gender-related disparity in outcomes of lower extremities peripheral arterial disease (PAD). Details of their study appear in the November issue of the Journal of Vascular Surgery®, published by the Society for Vascular Surgery®.

4 Nov 2010

Boston Scientific's Neurovascular business to be acquired by Stryker

Boston Scientific Corporation today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion, payable in cash, of which $1.4 billion is payable at closing and $100 million will be payable following the closing and upon the occurrence of the commercialization of the next-generation Target™ Detachable Coils and the transfer or separation of certain manufacturing facilities, which is anticipated to occur over a period of approximately 24 months.

From Stryker 29 Oct 2010

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular Congress 2010 this week.

25 Oct 2010

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.

12 Oct 2010

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010

New approach to evaluate risk of cardiovascular disease

A new approach to evaluating a person's risk of cardiovascular disease, stroke, high blood pressure, or heart failure is reported this month in the International Journal of Data Mining, Modelling and Management. The technique uses fuzzy logic to teach a neural network computer program to analyze patient data and spot correlations that can be translated into a risk factor for an individual.

16 Sep 2010

JHN launches network to advance neuroscience care

Jefferson Hospital for Neuroscience (JHN) is launching the Jefferson Neuroscience Network (JNN) to promote collaboration among area hospitals to advance neuroscience care throughout the region. Chestnut Hill Hospital is the first hospital to join JNN. Through this collaboration, Jefferson and Chestnut Hill will provide the most sophisticated care and expertise available to patients with time-sensitive neurovascular diseases.

9 Sep 2010

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.

3 Sep 2010

Genetic profiling to predict treatment benefits of ACE inhibitor therapy for CAD

The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.

31 Aug 2010

Nuokang's product pipeline candidates advance through SFDA review process

China Nuokang Bio-Pharmaceutical Inc., a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that two of its product pipeline candidates recently advanced through the next respective stages of the State Food and Drug Administration review process.

4 Aug 2010

ProTron Technologies creates Stethotron Intra-vascular Atherosclerotic Detector

Cardiovascular and cerebrovascular disease are the major causes of death in the world. Atherosclerotic plaque, the narrowing of blood vessels, causes audible turbulence in the bloodstream. Standard and electronic stethoscopes are designed to listen to heart and lung signals between 10-300 Hz. But as these waves do not travel in straight paths, and this frequency is a physiological sound, this uncertainty of origin may cause diagnosis errors.

27 Jul 2010

Scientists update criteria for diagnosis of Alzheimer's disease

Scientists at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 today presented the first draft reports from three workgroups convened by the National Institute on Aging and the Alzheimer's Association to update the diagnostic criteria for Alzheimer's disease for the first time in 25 years.

14 Jul 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Migraine sufferers who experienced abuse and neglect as children have a greater risk of cardiovascular (CV) disease including stroke and myocardial infarction (MI) among others, say scientists presenting data at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week.

23 Jun 2010